R&D News & Analysis
8 articles
Market Mood
Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield
Sanofi SA (NASDAQ: SNY) announced the appointment of Paulo Fontoura as Executive Vice President and Global Head of Research & Development effective September 1. Fontoura will oversee the company's end-to-end innovation engine across multiple therapeutic areas, succeeding Dr. Houman Ashrafian. The appointment is significant as Sanofi progresses in its R&D transformation and aims to accelerate the development of new medicines. Additionally, MacroGenics confirmed it will receive $24.5 million from Sanofi due to regulatory milestone payments related to the FDA's accelerated approval of TZIELD.
Read More: Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield
Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
Medtronic plc (MDT) CEO Geoffrey Martha announced on June 8 that the company expects a tariff impact of $250 million for fiscal 2027, down from a previous estimate of $300 million. This figure includes $75 million expected in the first quarter. The reduction is due to supply chain adjustments, although Martha indicated that future tariff threats could alter these forecasts. Medtronic allocates $5 billion to $6 billion annually for innovation and reported a 78% revenue increase in cardiac ablation amidst ongoing cost pressures.
Read More: Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
AMD (AMD) Stock Up 100-Fold, No Dividends Expected Soon
Advanced Micro Devices (AMD) stock has increased more than 100-fold over the decade ending in 2026, driven by demand for its CPUs and GPUs. The company experienced record revenue and profit growth in 2025, with R&D spending exceeding $8.09 billion, up from $1.983 billion in 2020. Despite its cash reserves, AMD does not plan to pay dividends and is focusing on stock repurchase programs. The company aims to reinvest earnings into its core business, particularly in AI-related research and development.
Read More: AMD (AMD) Stock Up 100-Fold, No Dividends Expected Soon
Unilever (UL) Announces New U.S. Research Facility Expansion
Unilever (UL) has announced plans to construct a new research facility in the U.S. This move is part of their strategy to enhance product innovation and maintain competitiveness in the market. Details regarding the investment amount, timeline for completion, and specific location have not been disclosed. The establishment of this facility could potentially influence Unilever’s R&D capabilities and market presence positively.
Read More: Unilever (UL) Announces New U.S. Research Facility Expansion
EnergyPathways Appoints Chief Scientific Adviser for Growth
EnergyPathways has appointed a new chief scientific adviser to enhance its research and development efforts. This appointment aims to strengthen the company's strategic initiatives and align its R&D goals with market demands. The addition of the new adviser is part of a broader effort to innovate within the energy sector, although specific financial metrics or forecasts were not disclosed. This strategic move is expected to positively influence EnergyPathways' market position and operational capabilities moving forward.
Read More: EnergyPathways Appoints Chief Scientific Adviser for Growth
Velmenni Research secures funding to enhance AI development
Velmenni Research & Development Pvt Ltd has successfully raised $5 million in funding to further its artificial intelligence projects. This investment signifies potential growth in the AI sector, highlighting increased investor interest in companies focused on innovative technologies. The funding will be utilized to expand their R&D capabilities and accelerate the development of new AI applications. Such advancements may influence market dynamics in the tech sector, particularly for companies engaged in the AI space.
Read More: Velmenni Research secures funding to enhance AI development
Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025
Legend Biotech Corporation (LEGN) announced financial results for 2025, achieving $1.9 billion in net trade sales from its CARVYKTI therapy, including ~$555 million in Q4. The company reported a collaboration revenue increase to $277.6 million in the final quarter. With over 10,000 patients treated and a global footprint expanding to 294 sites across 14 markets, LEGN is positioned for growth. Additionally, the company opened a new 31,000-square-foot R&D facility in Philadelphia to support its pipeline advancements.
Read More: Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025
Europe's Pharma Sector Facing Decline Amid U.S. Policies and China's Rise
The pharmaceutical industry in Europe is experiencing significant challenges due to President Trump's trade policies and China's rapid advancements in biotech. Since 1990, Europe’s share of global research and development has decreased from nearly 50% to 26%, while the U.S. share increased to 55%. These changes are prompting global pharmaceutical companies to reconsider their investment strategies, particularly as U.S. tariffs on branded drugs may reach up to 100%. As a result, Europe risks falling behind in critical medicine launches and innovation opportunities.
Read More: Europe's Pharma Sector Facing Decline Amid U.S. Policies and China's Rise